We are excited to launch this highly informative document which fulfils one of the Northern Alliance Work Package 4 main objectives. It supports ATMP developers and NHS Trusts and Boards to accelerate the adoption of these innovative medicines, by providing guidance on regulatory, health economic and commissioning processes and pathways. This guide has been prepared by experts from NA-ATTC, Chiesi Limited, Bresmed Health Solutions, University of Leeds and the Cell and Gene Therapy Catapult. Guidance is provided relating to best practice for developers regarding quality of life approaches for ATMPs, production of a health economic framework for ATMPs and production of a guidance note for developers on how to ensure their product is identified in horizon scanning processes by HTA bodies.
